The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Open accessPublished version of a preprint
Abstract
Oncogenic KRAS (KRAS*) is a key tumor maintenance gene in pancreatic ductal adenocarcinoma (PDAC), motivating pharmacologic targeting of KRAS* and its effectors. Here, we explored mechanisms involving the tumor microenvironment (TME) as a potential basis for resistance to targeting KRAS*. Using the inducible KrasG12D;Trp53−/− PDAC mouse model, gain-of-function screens of epigenetic regulators identified HDAC5 as the top hit enabling KRAS* independent tumor growth. HDAC5-driven escaper tumors showed a prominent neutrophil-to-macrophage switch relative to KRAS*-driven tumors. Mechanistically, HDAC5 represses Socs3, a negative regulator of chemokine CCL2, resulting in increased CCL2, which recruits CCR2+ macrophages. Correspondingly, enforced Ccl2 promotes macrophage recruitment into the TME and enables tumor recurrence following KRAS* extinction. These tumor-associated macrophages in turn provide cancer cells with trophic support including TGFβ to enable KRAS* bypass in a SMAD4-dependent manner. Our work uncovers a KRAS* resistance mechanism involving immune cell remodeling of the PDAC TME. Significance: Although KRAS* is required for PDAC tumor maintenance, tumors can recur following KRAS* extinction. The capacity of PDAC cancer cells to alter the TME myeloid cell composition to support KRAS*-independent tumor growth illuminates novel therapeutic targets that may enhance the effectiveness of therapies targeting KRAS* and its pathway components. See related commentary by Carr and Fernandez-Zapico, p. 910. This article is highlighted in the In This Issue feature, p. 890
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This discovery gains significance considering the ability of KRAS G12D to boost GM-CSF production in PDAC cancer cells, thereby attracting immunosuppressive myeloid cells that can dampen the activity of CD8 T-cells [54].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“YAP, a pivotal EMT regulator gene, can restore oncogenicity in murine tumors that have lost KRAS [54,131].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“In HDAC5-rich tumors, these macrophages increase TGFβ production, triggering pSMAD3/SMAD4 signaling in cancer cells, and bypassing the need for KRAS.”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, HDAC5 suppresses SOCS3, boosting CCL2 and CCL7 expression.”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“Gain-of-function screens of epigenetic regulators in KRAS-mutant PDAC models identified HDAC5 as a driver of resistance to KRAS inhibition within the tumor microenvironment [54].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, studies of the iKras mouse model have highlighted myriad mechanisms to enable bypass of oncogenic KRAS addiction, including the adoption of a KRAS-independent cell state dependent on oxidative phosphorylation (5), induction of SMARCB–MYC-network-driven mesenchymal reprogramming (38), activation of the TGFβ-SMAD3/4 axis via TME remodeling (39), and USP21-mediated upregulation of macrop”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [39]
In the citing paper
“In a KRASG12D mutation driven PDAC mice model, immune suppressive cytokines IL-4 and IL-13 and remodeling of the myeloid cell composition in TME have been demonstrated40,41.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [40]
In the citing paper
“Overexpression of the histone deacetylase HDAC5 also enables bypass of KRAS extinguishment through cytokine-mediate remodeling of the tumor microenvironment (86).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [86]
In the citing paper
“Inhibitors of the HDAC5-SMAD4 pathways in combination with KRAS (G12D) inhibition have synergistic antitumor effects in an isogenic PDAC model [146].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [146]
In the citing paper
“These tumor-associated macrophages (TAMs) provide cancer cells with TGFβ that promotes KRAS mutation-independent PDAC cell growth after KRAS mutation-targeted inhibition.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [146]
In the citing paper
“Histone deacetylase 5 (HDAC5)-induced bypass promotes macrophage recruitment into the TME and enables tumor recurrence following the extinction of KRAS (G12D) [146].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 3×
“485 Additionally, we propose that SMAD4 status, which is a frequent deletion event in PDAC (2), 486 should be assessed as patient inclusion criteria for clinical trials testing KRAS* inhibitors.”
BackgroundMethodTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,350
A survey of best practices for RNA-seq data analysis
Conesa, A., Madrigal, P., Tarazona, S., Gomez-Cabrero, D., Cervera, A., McPherson, A., Szcześniak, M. W., Gaffney, D. J., Elo, L. L., Zhang, X., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0881-8 · Cited by 2,794
Haberland, M., Montgomery, R. L., & Olson, E. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,600
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationGlutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Self-citationMacropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259
Self-citationAguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 1×
“In mouse 59 models, KRAS* serves as a tumor initiating event and, together with loss of tumor suppressor 60 genes, can drive advanced disease that recapitulates well the biology of human PDAC (3, 4).”
BackgroundSelf-citationUnderstanding and targeting resistance mechanisms in NSCLC
Rotow, J. K., & Bivona, T. G. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.84 · Cited by 997
Betaglycan presents ligand to the TGFβ signaling receptor
López‐Casillas, F., Wrana, J. L., & Massagué, J. (1993) · Cell · doi:10.1016/0092-8674(93)90368-z · Cited by 892
Nywening, T. M., Wang‐Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 840
Zhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J. R., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.014 · Cited by 828
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770
Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 4×
“The iKPC cells were transfected with luciferase-mCherry reporter as described previously (17).”
BackgroundMethodInfluentialSelf-citationS100A8 and S100A9 in inflammation and cancer
Gebhardt, C., Németh, J., Angel, P., & Hess, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.05.017 · Cited by 696
Bardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674
Self-citationClass II histone deacetylases: versatile regulators
Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 632
Targeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras‐Raballand, A., Cohen, R., Cros, J. F., Faivre, S. J., Raymond, É., & Gramont, A. D. E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 631
Bardeesy, N. M., Aguirre, A. J., Chu, G. C., Cheng, K., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 584
Self-citationUnraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706487104 · Cited by 566
SOCS3, a Major Regulator of Infection and Inflammation
Carow, B., & Rottenberg, M. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00058 · Cited by 555 · cited 1×
“Among the 306 top 5 candidates, we focused on Zfp36 and Socs3, because Zfp36 is known to promote AU-rich 307 mRNA decay including Ccl2 mRNA in macrophages(33), and SOCS3 is known to repress STAT 308 pathway activation (34) and negatively regulates IFNβ induced expression of Ccl2 and Cxcl10 in 309 primary astrocytes (3…”
BackgroundMacrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
Halbrook, C. J., Pontious, C., Kovalenko, I., Lapienyte, L., Dreyer, S., Lee, H.-J., Thurston, G., Zhang, Y., Lazarus, J., Sajjakulnukit, P., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.001 · Cited by 419
Brooks, S. A., & Blackshear, P. J. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.02.003 · Cited by 392
Liposomes for Specific Depletion of Macrophages from Organs and Tissues
van Rooijen, N., & van Kesteren-Hendrikx, E. M. L. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-360-2_13 · Cited by 381
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
Garber, M., Yosef, N., Goren, A., Raychowdhury, R., Thielke, A., Guttman, M., Robinson, J., Minie, B., Chevrier, N., Itzhaki, Z., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.07.030 · Cited by 369
Ferrari, G. M., Ferrari, G., Cook, B., Terushkin, V., Pintucci, G., & Mignatti, P. (2008) · Nature Precedings · doi:10.1002/jcp.21706 · Cited by 348
Coulouarn, C., Factor, V. M., & Thorgeirsson, S. S. (2008) · Hepatology · doi:10.1002/hep.22283 · Cited by 345
Guido, C., Whitaker‐Menezes, D., Capparelli, C., Balliet, R. M., Zhao, L., Pestell, R. G., Howell, A., Aquila, S., Andò, S., Martinez‐Outschoorn, U., et al. (2012) · Cell Cycle · doi:10.4161/cc.21384 · Cited by 333
Dey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0297 · Cited by 213 · cited 1×
“KRAS* also drives cell autonomous expression of type I cytokine receptor 65 complexes to receive growth signals from the tumor microenvironment (TME) to enhance 66 glycolysis (8).”
BackgroundSelf-citationK-ras mutations in pancreatic ductal proliferative lesions.
Klimstra, D. S., & Longnecker, D. S. (1994) · PubMed · Cited by 197
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Zhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.018 · Cited by 180
The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
Ahmed, S., Bradshaw, A.-D., Gera, S., Dewan, M., & Xu, R. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6010005 · Cited by 174
Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells
Zdanov, S., Mandapathil, M., Eid, R. A., Adamson-Fadeyi, S., Wilson, W., Qian, J., Carnie, A., Tarasova, N. I., Mkrtichyan, M., Berzofsky, J. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0241 · Cited by 157
Roy, N., Malik, S., Villanueva, K. E., Urano, A., Lu, X., Von Figura, G., Seeley, E. S., Dawson, D. W., Collisson, E. A., & Hebrok, M. (2015) · Genes & Development · doi:10.1101/gad.256628.114 · Cited by 155
Expression and Functional Significance of SOCS-1 and SOCS-3 in Astrocytes
Qin, H., Niyongere, S., Lee, S. J., Baker, B. J., & Benveniste, E. N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3167 · Cited by 129
Ko, A. H., Bekaii‐Saab, T., Ziffle, J. V., Mirzoeva, O. K., Joseph, N. M., Talasaz, A. H., Kühn, P., Tempero, M. A., Collisson, E. A., Kelley, R. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0979 · Cited by 121
USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation
Hou, P., Ma, X., Zhang, Q., Wu, C.-J., Liao, W., Li, J., Wang, H., Zhao, J., Zhou, X., Guan, C., et al. (2019) · Genes & Development · doi:10.1101/gad.326314.119 · Cited by 96
Self-citationMatsuo, Y., Campbell, P. M., Brekken, R. A., Sung, B., Ouellette, M. M., Fleming, J. B., Aggarwal, B. B., Der, C. J., & Guha, S. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0577 · Cited by 91
Nagathihalli, N. S., Castellanos, J. A., Lamichhane, P., Messaggio, F., Shi, C., Dai, X., Rai, P., Chen, X., VanSaun, M. N., & Merchant, N. B. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0634 · Cited by 90
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
Echevarría-Vargas, I. M., Reyes-Uribe, P. I., Guterres, A. N., Yin, X., Kossenkov, A. V., Liu, Q., Zhang, G., Krepler, C., Cheng, C., Wei, Z., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708446 · Cited by 89
Pettazzoni, P., Viale, A., Shah, P. K., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 83
Self-citationFujimura, K., Choi, S., Wyse, M. M., Strnádel, J., Wright, T., & Klemke, R. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.687418 · Cited by 82
Khursheed, M., Kolla, J. N., Kotapalli, V., Gupta, N. A., Gowrishankar, S., Uppin, S. G., Sastry, R. A., Koganti, S. B., Sundaram, C. S., Pollack, J. R., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.200 · Cited by 67
Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer
Feng, W., Zhang, B., Cai, D., & Zou, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.012 · Cited by 64
S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB
Feng, P., Yu, C.-T., Chen, K.-Y., Luo, C.-S., Wu, S. M., Liu, C., Kuo, L.-W., Chan, Y., Chen, T.-T., Chang, C.-C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24146 · Cited by 46
Flagged first, then by citations
Cited by
Sorted by citations
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“…including the adoption of a KRAS-independent cell state dependent on oxidative phosphorylation (5), induction of SMARCB–MYC-network-driven mesenchymal reprogramming (38), activation of the TGF β - SMAD3/4 axis via TME remodeling (39), and USP21-mediated upregulation of macropinocytosis (40).”
BackgroundEmerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 282
Self-citation
Metadata
- Authors
- Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., Kalluri, R., Zhang, J., Jiang, S., Spring, D. J., Wang, Y. A., & DePinho, R. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Wang, Y. Alan
- DePinho, Ronald A.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-07-01
- Volume
- 10
- Issue
- 7
- Pages
- 1058-1077
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7334087
- OpenAlex
- W3019483263
- Cited by
- 154
- References
- 57
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 25 · 2020: 7
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (P30 CA016672, P01 CA117969, R01 CA225955, R01 CA231349)
- Hirshberg Foundation for Pancreatic Cancer Research
- Emerson Collective
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- pancreatic ductal adenocarcinoma, KRAS, tumor microenvironment, HDAC5, epigenetic regulators, tumor-associated macrophages, MCP-1, CCR2, SOCS3, TGF-beta, SMAD4, tumor recurrence
- MeSH terms
- Humans, Oncogenes, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
